« Return to News | Technology Solutions | CROs/Service Providers

Kendle Updates Biostatistics Platform

Wednesday, March 17, 2010 07:00 AM

Cincinnati-based contract research organization (CRO) Kendle has implemented a new biostatistics infrastructure that the company said will enhance the analysis and delivery of clinical trial data for customers.

The new platform allows Kendle’s biostatistics and scientific programming staff to simultaneously access clinical trial data from anywhere in the world. The system will improve network performance and bandwidth availability, as well as reduce licensing requirements.

"With this new environment, data will be processed at the server level much faster than ever before, greatly improving the productivity of our teams around the world and expediting the delivery of quality data to our customers," said John A. Whitaker, Ph.D., vice president, biostatistics and statistical programming, in a statement.  "This investment allows Kendle to provide a more globally integrated solution to meet our customers' needs anywhere, any time."

The new system will also enable Kendle to improve its growing operations in India, the CRO said.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.